Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Randomized Trial of Gemcitabine + Docetaxel With or Without Bevacizumab (Onbevzi) in Previously Treated Soft Tissue Sarcoma
KCT0011910Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in soft tissue sarcoma (STS), sponsored by Boryung. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on KCT0011910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011910.